FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285498294> ?p ?o ?g. }

• W4285498294 endingPage "e971" @default.
• W4285498294 startingPage "e959" @default.
• W4285498294 abstract "Atrial fibrillation (AF) is a recognized adverse consequence associated with all Bruton's tyrosine kinase inhibitors used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); however, real-world time to discontinuation (TTD) and time to next treatment (TTNT) of CLL/SLL patients with a high baseline AF/stroke risk remain unknown.Patients with CLL/SLL from a nationwide electronic health record-derived database (February 12, 2013-January 31, 2021) initiating first-line (1L) or second or later-line (2L+) treatment with ibrutinib or other regimens on or after February 12, 2014 (index date) were analyzed. Kaplan-Meier survival analysis was used to assess TTD and TTNT among all patients, patients with high AF risk (CHARGE-AF risk score ≥10.0%), and patients at high risk of stroke (CHA2DS2-VASc risk score ≥3 [females] or ≥2 [males]).In 1L/2L+, 2190/1851 patients received ibrutinib and 4388/4135, were treated with other regimens. Median TTD for ibrutinib was similar regardless of AF/stroke-related risk (1L: all patients, 15.7 months; high AF risk, 11.7 months; high stroke risk, 13.7 months; similar results in 2L+). Median TTNT was significantly longer for ibrutinib vs. other regimens (1L: not reached vs. 45.9 months; 2L+: not reached vs. 23.6 months; both P < .05), including among those with high AF/stroke risk. TTNT was similar between all patients and high-risk cohorts in 1L and 2L+ (all P > .05).This study highlights that elevated baseline AF/stroke-related risk does not adversely impact TTD and TTNT outcomes associated with ibrutinib use. Additionally, TTNT was significantly longer for patients treated with ibrutinib vs. other regimens." @default.
• W4285498294 created "2022-07-15" @default.
• W4285498294 creator A5000027607 @default.
• W4285498294 creator A5009804147 @default.
• W4285498294 creator A5012473008 @default.
• W4285498294 creator A5019269759 @default.
• W4285498294 creator A5019906660 @default.
• W4285498294 creator A5044422851 @default.
• W4285498294 creator A5054604090 @default.
• W4285498294 creator A5055025408 @default.
• W4285498294 creator A5056116635 @default.
• W4285498294 creator A5075436982 @default.
• W4285498294 creator A5087574931 @default.
• W4285498294 creator A5089322911 @default.
• W4285498294 date "2022-11-01" @default.
• W4285498294 modified "2023-10-18" @default.
• W4285498294 title "Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke" @default.
• W4285498294 cites W1999128869 @default.
• W4285498294 cites W1999782555 @default.
• W4285498294 cites W2024216962 @default.
• W4285498294 cites W2093745295 @default.
• W4285498294 cites W2097173178 @default.
• W4285498294 cites W2108206643 @default.
• W4285498294 cites W2162586165 @default.
• W4285498294 cites W2233614027 @default.
• W4285498294 cites W2514172728 @default.
• W4285498294 cites W2550091596 @default.
• W4285498294 cites W2590804070 @default.
• W4285498294 cites W2739393823 @default.
• W4285498294 cites W2806627663 @default.
• W4285498294 cites W2888047356 @default.
• W4285498294 cites W2897636215 @default.
• W4285498294 cites W2900434412 @default.
• W4285498294 cites W2902484351 @default.
• W4285498294 cites W2902706178 @default.
• W4285498294 cites W2907375267 @default.
• W4285498294 cites W2941780980 @default.
• W4285498294 cites W2947611756 @default.
• W4285498294 cites W2964876593 @default.
• W4285498294 cites W2966190920 @default.
• W4285498294 cites W2970731184 @default.
• W4285498294 cites W2983802128 @default.
• W4285498294 cites W2988869192 @default.
• W4285498294 cites W2999417355 @default.
• W4285498294 cites W3012011926 @default.
• W4285498294 cites W3038687742 @default.
• W4285498294 cites W3094710184 @default.
• W4285498294 cites W3096662075 @default.
• W4285498294 cites W3097160786 @default.
• W4285498294 cites W3108628542 @default.
• W4285498294 cites W3137277615 @default.
• W4285498294 cites W3139157067 @default.
• W4285498294 cites W3157950990 @default.
• W4285498294 cites W3167803739 @default.
• W4285498294 cites W3189823930 @default.
• W4285498294 cites W4281784552 @default.
• W4285498294 cites W4282941415 @default.
• W4285498294 doi "https://doi.org/10.1016/j.clml.2022.07.004" @default.
• W4285498294 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35973891" @default.
• W4285498294 hasPublicationYear "2022" @default.
• W4285498294 type Work @default.
• W4285498294 citedByCount "4" @default.
• W4285498294 countsByYear W42854982942023 @default.
• W4285498294 crossrefType "journal-article" @default.
• W4285498294 hasAuthorship W4285498294A5000027607 @default.
• W4285498294 hasAuthorship W4285498294A5009804147 @default.
• W4285498294 hasAuthorship W4285498294A5012473008 @default.
• W4285498294 hasAuthorship W4285498294A5019269759 @default.
• W4285498294 hasAuthorship W4285498294A5019906660 @default.
• W4285498294 hasAuthorship W4285498294A5044422851 @default.
• W4285498294 hasAuthorship W4285498294A5054604090 @default.
• W4285498294 hasAuthorship W4285498294A5055025408 @default.
• W4285498294 hasAuthorship W4285498294A5056116635 @default.
• W4285498294 hasAuthorship W4285498294A5075436982 @default.
• W4285498294 hasAuthorship W4285498294A5087574931 @default.
• W4285498294 hasAuthorship W4285498294A5089322911 @default.
• W4285498294 hasBestOaLocation W42854982941 @default.
• W4285498294 hasConcept C126322002 @default.
• W4285498294 hasConcept C127413603 @default.
• W4285498294 hasConcept C143998085 @default.
• W4285498294 hasConcept C2777938653 @default.
• W4285498294 hasConcept C2778461978 @default.
• W4285498294 hasConcept C2778715236 @default.
• W4285498294 hasConcept C2779161974 @default.
• W4285498294 hasConcept C2779668873 @default.
• W4285498294 hasConcept C2779878957 @default.
• W4285498294 hasConcept C2780645631 @default.
• W4285498294 hasConcept C44249647 @default.
• W4285498294 hasConcept C71924100 @default.
• W4285498294 hasConcept C78519656 @default.
• W4285498294 hasConceptScore W4285498294C126322002 @default.
• W4285498294 hasConceptScore W4285498294C127413603 @default.
• W4285498294 hasConceptScore W4285498294C143998085 @default.
• W4285498294 hasConceptScore W4285498294C2777938653 @default.
• W4285498294 hasConceptScore W4285498294C2778461978 @default.
• W4285498294 hasConceptScore W4285498294C2778715236 @default.
• W4285498294 hasConceptScore W4285498294C2779161974 @default.
• W4285498294 hasConceptScore W4285498294C2779668873 @default.

• next